Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk
详细信息 查看全文
- 作者：Kunio Sugahara ; Yasuhiro Maeda ; Kyoko Shimano ; Akira Mogami ; Hirotoshi Kataoka ; Kei Ogawa ; Kumiko Hikida ; Hiroshi Kumagai ; Mahoko Asayama ; Toshinobu Yamamoto ; Tomohiko Harada ; Pingping Ni ; Shinsuke Inoue and Atsuhiro Kawaguchi
- 刊名：British Journal of Pharmacology
- 出版年：2017
- 出版时间：January 2017
- 年：2017
- 卷：174
- 期：1
- 页码：15-27
- 全文大小：703K
- ISSN：1476-5381
文摘
We conducted preclinical and clinical studies to examine the pharmacological, particularly cardiac, effects of amiselimod (MT-1303), a second-generation sphingosine 1-phosphate (S1P) receptor modulator, designed to reduce the bradycardia associated with fingolimod and other S1P receptor modulators.